


Suspected Urinary Tract Infection

Clinical Assessment/ Management tool for Children



Management - Primary Care and Community Settings



Suspected Urinary Tract Infection

Clinical Assessment/ Management tool for Children

Management - Primary Care and Community Settings



Suspected Urinary Tract Infection

Clinical Assessment/ Management tool for Children



Management - Primary Care and Community Settings

Table 1: Normal Paediatric Values:

(APLS*)	Respiratory Rate at rest (b/min)	Heart Rate (b/min)
< 1 year	30 - 40	110 - 160
1 - 2 years	25 - 35	100 - 150
> 2 -5 years	25 - 30	95 - 140
5 - 12 years	20 - 25	80 - 120
Over 12	15 - 20	60 - 100

* Advanced Paediatric Life Support The Practical Approach Fifth Edition Advanced Life Support Group Edited by Martin Samuels; Susan Wieteska Wiley-Blackwell / 2011 BMJ Books.

Box 1

Urine collection and preservation

- Clean catch is recommended method. Gentle suprapubic cutaneous stimulation using gauze soaked in cold fluid helps trigger voiding*
- If absolutely unavoidable pads / bags must be put on clean skin and checked very regularly to minimise contamination risk
- Unless urine can get straight to lab preservation in a boric acid (red top) container will allow 48 hours delay



*Urine collection in infants
[Kaufmann et al BMJ open](#)

Box 2

Treatment

≤3 month: treat as pyelonephritis (refer to paediatrics)

>3 months of age:

If unable to tolerate oral Abs or systemically unwell (suggestive of bacteraemia), requires consideration of IV antibiotics— refer to paediatrics.

- Lower UTI: Trimethoprim, if previous treatment with trimethoprim in the last 3 months, use nitrofurantoin if able to swallow tablets and [egfr] >45ml/minute. If first line antibiotics are not suitable or no improvement in 48 hours consider second line antibiotics such nitrofurantoin (if not used first line), cefalexin, or amoxicillin (if culture susceptible)
- Upper UTI/Pyelonephritis: Cefalexin, or co-amoxiclav (if sensitivity known)
- For more information about treatment, see BCICB guidelines for antibiotic prescribing in the community below.

Box 3

Who needs imaging?

Ultrasound:

- Under 6 months - within 6 weeks, acutely if atypical** or recurrent*** infection
- Over 6 months - not routinely, acutely if atypical** infection, within 6 weeks if recurrent*** infection.

DMSA:

- Atypical** infections under 3 years
- Recurrent*** infections at all ages

MCUG:

- Under 6 months with atypical** or recurrent*** infections
- Consider in all under 6 months with abnormal ultrasound.
- Consider 6-18 months if non E-Coli UTI, poor flow, dilatation on USS or family history VUR

**Atypical UTI = seriously ill/ sepsis, poor urine flow, non E-Coli, abdominal or bladder mass, raised creatinine, failure to respond in 48 hours
*** Recurrent UTIs = ≥3 lower UTIs, ≥2 upper UTIs or 1 upper and 1 lower UTI

Box 4

Who needs paediatric follow-up?

- Children with recurrent UTIs not responding to simple advice (see risk factors)
- Children with abnormal imaging or if appropriate imaging cannot be arranged in primary care

Box 5

Risk factors for recurrent UTIs

- Constipation
- Poor fluid intake
- Infrequent voiding esp at school (holding on)
- Irritable bladder (can happen following UTI)
- Neuropathic bladder
 - Examine spine
- Genitourinary abnormalities
 - Examine genitalia

For further information, see NICE guidelines: <https://pathways.nice.org.uk/pathways/urinary-tract-infection-in-under-16s#path=view%3A/pathways/urinary-tract-infection-in-under-16s/diagnosing-urinary-tract-infection-in-under-16s.xml&content=view-index>

Suspected Urinary Tract Infection

Clinical Assessment/ Management tool for Children



Management - Primary Care and Community Settings

BCICB guidelines for antibiotic prescribing in the community.

LOWER UTI

ORAL FIRST LINE:

NITROFURANTOIN OR TRIMETHOPRIM (IF LOW RISK OF RESISTANCE OR LIQUID IS PREFERRED).

Trimethoprim

Child 3–5 months

4 mg/kg twice daily (max. per dose 200 mg) for 3 days, alternatively 25 mg twice daily for 3 days.

Child 6 months–5 years

4 mg/kg twice daily (max. per dose 200 mg) for 3 days, alternatively 50 mg twice daily for 3 days.

Child 6–11 years

4 mg/kg twice daily (max. per dose 200 mg) for 3 days, alternatively 100 mg twice daily for 3 days.

Child 12–15 years

200 mg twice daily for 3 days.

Child 16–17 years

200 mg twice daily for 3 days (7 days in males).

Nitrofurantoin – use capsules where possible, oral solutions have significant high cost implication

- Using immediate-release medicines

Child 3 months–11 years

750 micrograms/kg 4 times a day for 3 days.

Child 12–15 years

50 mg 4 times a day for 3 days (7 days if pregnant).

Child 16–17 years

50 mg 4 times a day for 3 days (7 days in males and if pregnant).

- Using modified-release medicines

Child 12–15 years

100 mg twice daily for 3 days (7 days if pregnant).

Child 16–17 years

100 mg twice daily for 3 days (7 days in males and if pregnant).

ORAL SECOND LINE (IF NO IMPROVEMENT AFTER AT LEAST 48 HOURS OR FIRST LINE NOT SUITABLE):

NITROFURANTOIN (IF NOT USED FIRST LINE) OR AMOXICILLIN (IF CULTURE SUSCEPTIBLE) OR CEFALEXIN.

Amoxicillin

Child 3–11 months

125 mg 3 times a day for 3 days.

Child 1–4 years

250 mg 3 times a day for 3 days.

Child 5–15 years

500 mg 3 times a day for 3 days. (if pregnant for 7 days)

Cefalexin

Child 3–11 months

12.5 mg/kg twice daily, alternatively 125 mg twice daily for 3 days.

Child 1–4 years

12.5 mg/kg twice daily, alternatively 125 mg 3 times a day for 3 days.

Child 5–11 years

12.5 mg/kg twice daily, alternatively 250 mg 3 times a day for 3 days.

Child 12–15 years

500 mg twice daily for 3 days. (if pregnant for 7 days)

Suspected Urinary Tract Infection

Clinical Assessment/ Management tool for Children



Management - Primary Care and Community Settings

ACUTE PYELONEPHRITIS

CHILDREN AGED 3 MONTHS TO UNDER 16 YEARS

ORAL FIRST LINE:

CEFALEXIN, OR CO-AMOXICLAV (IF SENSITIVITY KNOWN).

Cefalexin

By mouth

Child 3–11 months

12.5 mg/kg twice daily for 7 to 10 days, alternatively 125 mg twice daily; increased if necessary to 25 mg/kg 2–4 times a day (max. per dose 1 g 4 times a day), increased dose used in severe infections.

Child 1–4 years

12.5 mg/kg twice daily, alternatively 125 mg 3 times a day for 7 to 10 days; increased if necessary to 25 mg/kg 2–4 times a day (max. per dose 1 g 4 times a day), increased dose used in severe infections.

Child 5–11 years

12.5 mg/kg twice daily, alternatively 250 mg 3 times a day for 7 to 10 days; increased if necessary to 25 mg/kg 2–4 times a day (max. per dose 1 g 4 times a day), increased dose used in severe infections.

Child 12–17 years

500 mg 2–3 times a day for 7 to 10 days; increased to 1–1.5 g 3–4 times a day, increased dose used in severe infections.

CO-AMOXICLAV (doses for 125/31 suspension)

Child 3–11 months

0.25 mL/kilogram 3 times a day for 7 to 10 days, dose doubled in severe infection.

Child 1–5 years

0.25 mL/kilogram 3 times a day, alternatively 5 mL 3 times a day for 7 to 10 days, dose doubled in severe infection.

CO-AMOXICLAV (doses for 250/62 suspension)

Child 6–11 years

0.15 mL/kilogram 3 times a day, alternatively 5 mL 3 times a day for 7 to 10 days, dose doubled in severe infection.

CO-AMOXICLAV TABLETS

Child 12–15 years

250/125 mg 3 times a day for 7–10 days, alternatively 500/125 mg 3 times a day for 7–10 days.

Child 16–17 years

500/125 mg 3 times a day for 7–10 days.